TRPA1 promotes cisplatin-induced acute kidney injury via regulating the endoplasmic reticulum stress-mitochondrial damage

Fei Deng, Heping Zhang, Wei Zhou, Shijie Ma, Yuwei Kang, Wei Yang, Liangbin Zhao, Wei QinJournal of Translational Medicine 2023 · DOI

Abstract: Our findings suggest that TRPA1 enhances cisplatin-induced AKI via modulation of ERS and mitochondrial damage.

Introduction

Cisplatin remains a cornerstone of cancer chemotherapy, yet its clinical utility is severely hampered by nephrotoxicity; approximately 20–30% of patients develop acute kidney injury (AKI). While oxidative stress and inflammation are known contributors, the precise molecular "cross-talk" between cellular organelles during cisplatin-induced injury has remained elusive. This study identifies the Transient Receptor Potential Ankyrin-1 (TRPA1) cation channel as a central regulator that links endoplasmic reticulum (ER) stress to mitochondrial failure, driving renal tubular cell death.

Mechanistic Insights: The ERS-Mitochondrial Axis

The researchers discovered that TRPA1 activation triggers a destructive interaction between the ER and mitochondria. Cisplatin increases the contact area at the Mitochondria-Associated ER Membrane (MAM), the physical tether between these organelles. TRPA1 facilitates a massive influx of $Ca^{2+}$, which induces ER stress and upregulates the chaperone protein GRP75. This protein stabilizes the MAM, funneling lethal amounts of calcium into the mitochondria, leading to swelling, membrane potential collapse, and eventual burst.

Schematic representation of cisplatin-induced pathways in renal tubular cells leading to AKI, highlighting the roles of ER stress, inflammation, and mitochondrial dysfunction.

Methods

The study employed a dual-model approach to dissect these pathways:

  • In Vivo: Male C57BL/6 mice were treated with cisplatin to induce AKI. A subset of mice received the TRPA1 inhibitor HC-030031 to evaluate its protective effects.
  • In Vitro: Human renal tubular epithelial (HK-2) cells were used to observe molecular dynamics, including calcium flux and mitochondrial fission/fusion protein expression.

Key techniques included Transmission Electron Microscopy (TEM) to visualize MAM structural changes, Western blotting for stress markers (GRP78, CHOP), and JC-1 assays to measure mitochondrial membrane potential.

Experimental Results

Inhibition of TRPA1 provided significant protection against cisplatin-induced damage. In mouse models, the administration of HC-030031 significantly reduced serum creatinine (Scr) and blood urea nitrogen (BUN) levels. Histopathological analysis confirmed that TRPA1 inhibition preserved renal architecture, reducing tubular injury and protein cast formation. Furthermore, TUNEL staining demonstrated a marked decrease in the percentage of apoptotic cells in kidney tissues when TRPA1 was inhibited.

Quantitative and qualitative analysis of kidney function (Crea, Urea), histopathology, and apoptosis following cisplatin treatment and TRPA1 inhibition.

Discussion and Future Directions

The study highlights TRPA1 as a critical "lynchpin" in the progression of AKI. By shifting the mitochondrial balance away from fragmentation (fission) and toward repair (fusion), TRPA1 inhibition effectively breaks the "death spiral" between the ER and mitochondria.

While these results are promising, limitations remain. The transition from mouse models to human clinical trials requires careful evaluation of the safety and specificity of TRPA1 inhibitors. Future research should also investigate the optimal therapeutic window for administering these inhibitors alongside chemotherapy to maximize renal protection without compromising anti-tumor efficacy.

Summary updated

Abstract

Our findings suggest that TRPA1 enhances cisplatin-induced AKI via modulation of ERS and mitochondrial damage.
BibTeX
@article{deng2023trpa,
  author = {Fei Deng and Heping Zhang and Wei Zhou and Shijie Ma and Yuwei Kang and Wei Yang and Liangbin Zhao and Wei Qin},
  title = {{TRPA1 promotes cisplatin-induced acute kidney injury via regulating the endoplasmic reticulum stress-mitochondrial damage}},
  journal = {Journal of Translational Medicine},
  year = {2023},
  doi = {10.1186/s12967-023-04351-9},
}
Figure